Januvia
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Januvia (sitagliptin; Merck & Co) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels.
The franchise product Janumet/XR ([sitagliptin + metformin/XR]; Merck & Co) addresses the fact that Januvia is generally used as a second- or third-line treatment option as an add-on to metformin.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Januvia : Diabetes type 2
LIST OF FIGURES
10 Figure 1: Januvia brand franchise for type 2 diabetes – SWOT analysis
11 Figure 2: Datamonitor Healthcare drug assessment of Januvia
12 Figure 3: Datamonitor Healthcare drug assessment scorecard for Januvia
14 Figure 4: Januvia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
16 Figure 5: Janumet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
18 Figure 6: Ertugliflozin + sitagliptin sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Januvia franchise products
5 Table 2: Januvia drug profile
5 Table 3: Janumet/Janumet XR drug profile
7 Table 4: Overview of pivotal trial data for Januvia franchise in diabetes
15 Table 5: Januvia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
17 Table 6: Janumet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
19 Table 7: Ertugliflozin + sitagliptin sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Marizev 
Sign up to the